As many new adalimumab biosimilars have been hitting the market, three experts discuss current market trends and how their organizations are projecting the future impact of these biosimilar products. During this podcast, speakers discuss modeling strategies, planning for resources, and operational changes needed to support biosimilar adoption.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.